Results 11 to 20 of about 20,963 (287)

Remnant cholesterol is associated with cardiovascular mortality

Frontiers in Cardiovascular Medicine, 2022
BackgroundGenetic, observational, and clinical intervention studies indicate that circulating levels of remnant cholesterol (RC) are associated with cardiovascular diseases.
Kerui Zhang, Xiangyun Qi, Fuyu Zhu, Quanbin Dong, Zhongshan Gou, Fang Wang, Li Xiao, Menghuan Li, Lianmin Chen, Lianmin Chen, Yifeng Wang, Haifeng Zhang, Haifeng Zhang, Yanhui Sheng, Yanhui Sheng, Xiangqing Kong, Xiangqing Kong   +16 more
doaj   +4 more sources

Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk

International Journal of Molecular Sciences, 2023
Randomized clinical trials with statins and other lipid-lowering drugs have shown the presence of a “residual cardiovascular risk” in those treated to “target” for LDL-cholesterol. This risk is mainly associated to lipid components other than LDL and in particular to remnant cholesterol (RC) and to lipoproteins rich in triglycerides in fasting and non ...
Francesco Baratta, Nicholas Cocomello, Mattia Coronati, Domenico Ferro, Daniele Pastori, Francesco Angelico, Maria Del Ben   +6 more
openaire   +3 more sources

Increased estimated remnant-like particle cholesterol is associated with impaired coronary collateralization in patients with coronary chronic total occlusions

Diabetology & Metabolic Syndrome, 2022
Aims This study intends to explore whether, or to what extent, the estimated remnant-like particle cholesterol was associated with coronary collateralization in patients with chronic total occlusion lesions.
Ang Gao, Jinxing Liu, Yan Liu, Chengping Hu, Yong Zhu, Yujie Zhou, Hongya Han, Yingxin Zhao   +7 more
doaj   +1 more source

Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase [PDF]

, 2015
Background Statins are first-line therapy for cardiovascular disease prevention, but their systemic effects across lipoprotein subclasses, fatty acids, and circulating metabolites remain incompletely characterized.
Ala-Korpela, M, Casas, J-P, Chaturvedi, N, Fatemifar, G, Hingorani, AD, Hughes, AD, Jarvelin, M-R, Kahonen, M, Kangas, AJ, Kettunen, J, Kivimaki, M, Lawlor, DA, Lehtimaki, T, Mantyselka, P, Perola, M, Raitakari, OT, Salomaa, V, Sattar, N, Smith, GD, Soininen, P, Tiainen, M, Tillin, T, Tynkkynen, T, Vanhala, M, Wang, Q, Wurtz, P   +25 more
core   +2 more sources

Apolipoprotein E and Atherosclerosis: From Lipoprotein Metabolism to MicroRNA Control of Inflammation. [PDF]

, 2018
Apolipoprotein (apo) E stands out among plasma apolipoproteins through its unprecedented ability to protect against atherosclerosis. Although best recognized for its ability to mediate plasma lipoprotein clearance in the liver and protect against ...
Hasty, Hui, Hussain, Lin, Mahley, Pepe, Roselaar   +6 more
core   +2 more sources

Alterations of intestinal lipoprotein metabolism in diabetes mellitus and metabolic syndrome [PDF]

, 2015
Diabetes and metabolic syndrome are associated with abnormal postprandial lipoprotein metabolism, with a significant delay in the clearance of many lipid parameters, including triglycerides and chylomicrons.
ARCA, Marcello
core   +1 more source

Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease

Journal of the American College of Cardiology, 2020
Genetic, observational, and clinical intervention studies indicate that circulating levels of triglycerides and cholesterol transported in triglyceride-rich lipoproteins (remnant cholesterol) can predict cardiovascular events.This study evaluated the association of triglycerides and remnant cholesterol (remnant-C) with major cardiovascular events in a ...
Castañer, Olga, Pintó, Xavier, Subirana, Isaac, Amor, Antonio J., Ros, Emilio, Hernáez, Álvaro, Martínez-González, Miguel Ángel, Corella, Dolores, Salas-Salvadó, Jordi, Estruch, Ramón, Lapetra, José, Gómez-Gracia, Enrique, Alonso-Gomez, Angel M., Fiol, Miquel, Serra Majem, Luis, Corbella, Emili, Benaiges, David, Sorli, Jose V., Ruiz-Canela, Miguel, Babió, Nancy, Sierra, Lucas Tojal, Ortega, Emilio, Fitó, Montserrat   +22 more
openaire   +3 more sources

High Remnant Cholesterol Level Potentiates the Development of Hypertension [PDF]

Frontiers in Endocrinology, 2022
BackgroundEmerging evidence suggests an association between remnant cholesterol (RC) and vascular damage and hypertension. However, this association has not been explored in a large-scale population in China, and a temporal relationship between RC and hypertension also needs to be investigated.MethodsWe conducted a retrospective cross-sectional study ...
Ming-Ming Chen, Xuewei Huang, Chengsheng Xu, Xiao-Hui Song, Xiao-Hui Song, Ye-Mao Liu, Ye-Mao Liu, Dongai Yao, Huiming Lu, Gang Wang, Gui-Lan Zhang, Ze Chen, Ze Chen, Tao Sun, Tao Sun, Chengzhang Yang, Chengzhang Yang, Fang Lei, Juan-Juan Qin, Juan-Juan Qin, Yan-Xiao Ji, Yan-Xiao Ji, Peng Zhang, Peng Zhang, Peng Zhang, Xiao-Jing Zhang, Xiao-Jing Zhang, Xiao-Jing Zhang, Lihua Zhu, Lihua Zhu, Jingjing Cai, Jingjing Cai, Feng Wan, Feng Wan, Zhi-Gang She, Zhi-Gang She, Hongliang Li, Hongliang Li, Hongliang Li, Hongliang Li   +39 more
openaire   +3 more sources

Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9 [PDF]

, 2017
BACKGROUND: A beneficial effect on cardiovascular risk may be obtained by improving lipid-related serum lipoprotein functions such as high-density lipoproteins (HDLs) cholesterol efflux capacity (CEC) and serum cholesterol loading capacity (CLC) and by ...
Adorni, Maria Pia, Bernini, Franco, Ferri, Nicola, Izzo, Raffaele, Marchiano, Silvia, Rozza, Francesco, Trimarco, Valentina, Zimetti, Francesca   +7 more
core   +3 more sources

Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. [PDF]

, 2018
Despite reducing progression and promoting regression of coronary atherosclerosis, statin therapy does not fully address residual cardiovascular (CV) risk.
Brent Muhlestein, J, Budoff, Matthew, Le, Viet T, May, Heidi T, Nelson, John R, Roy, Sion   +5 more
core   +2 more sources